News

Monoclonal Antibodies As A Future Therapeutic Against Neurodegenerative Diseases

Monoclonal antibodies developed by a team of scientists at the NYU Langone Medical Center’s Center for Cognitive Neurology may be a stepping-stone towards potential new treatments against neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease. The majority of neurodegenerative diseases, such as Alzheimer’s, Lewy Body and other dementias, Parkinson’s and prion diseases…

Accera Announces 75% AD Patient Enrolment in Phase 3 NOURISH Study

Accera, Inc. a clinical-stage biotechnology company based in Broomfield, Colorado, recently announced that 75% of patients have been enrolled in its NOURISH AD Phase 3 clinical trial assessing the efficacy of its investigational compound AC-1204 for the treatment of Alzheimer’s disease (AD). The company is expecting to enroll a total…

Long-term Memories Maintained by Prion-like Proteins

Researchers from Columbia University Medical Center (CUMC) have released multiple study findings showing that long term memories are stored with the help of prion-like proteins called CPEB.  These CPEB proteins work to form long term memory in the same way as the mechanisms that cause mad cow disease, kuru, and other…